2021 ESMO congress

# 1172MO

# Durvalumab consolidation in patients with stage III non-resecable NSCLC with driver genomic alterations

M. Riudavets Melia[1], E. Auclin[2], M.A. Mosteiro Lamas[3], N. Dempsey[4], M. Majem[5], R. Lobefaro[6], R. Lopez Castro[7], J. Bosch Barrera[8], S. Pilotto[9], E. Escalera Martín[10], M. Tagliamento[11], J. Mosquera Martinez[12], G. Zalcman[13], E. Nadal[3], G. Lopes[4], D. Signorelli[6], M.R. Garcia Campelo[12], B. Besse[1], D. Planchard[1], L. Mezquita[14]

[1] Medical Oncology Department, Gustave Roussy Cancer Campus, Villejuif, France, [2] Medical Oncology Department, Hôpital Européen Georges Pompidou, Paris, France, [3] Medical Oncology Department, ICO - Institut Català d'Oncologia l'Hospitalet (Hospital Duran i Reynals), L'Hospitalet de Llobregat, Spain, [4] Medical Oncology Department, Sylvester Comprehensive Cancer Center - University of Miami, Miami, FL, USA, [5] Medical Oncology Department, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain, [6] Medical Oncology Department, Istituto Nazionale dei Tumori di Milano - Fondazione IRCCS, Milan, Italy, [7] Medical Oncology Department, Hospital Clínico Universitario de Valladolid, Valladolid, Spain, [8] Medical Oncology Department, ICO - Institut Català d'Oncologia Girona (Hospital Universitari Josep Trueta), L'Hospitalet de Llobregat, Spain, [9] Medical Oncology Department, University and Hospital Trust of Verona, Verona, Italy, [10] Medical Oncology Department, Hospital Clínico de Salamanca, Salamanca, Spain, [11] Medical Oncology Department, IRCCS Ospedale Policlinico San Martino, Genoa, Italy, [12] Medical Oncology Department, CHUAC - Complexo Hospitalario Universitario A Coruña, A Coruña, Spain, [13] Medical Oncology Department, Hôpital Bichat Claude Bernard, Paris, France[14] Medical Oncology Department, Hospital Clínic i Provincial de Barcelona, Barcelona, Spain

## Background

Durvalumab is the standard-of-care as consolidation therapy after chemo-radiation (ChRT) in stage III non-resecable non-small cell lung cancer (NSCLC). Its activity across NSCLC patients (pts) with genomic alterations (GA) is poorly characterized. We aimed to assess durvalumab outcomes in the context of oncogenic addition.

## Methods

Retrospective study of pts with stage III non-resecable NSCLC treated with durvalumab after ChRT between Apr/15 and Oct/20 at 25 centres from Europe and United States. Clinical and biological data were collected; driver GA (dGA) included *EGFR*/all-*BRAF*/all-*KRAS* mutations (m) and *ALK/ROS1* rearrangements (r). Radiological response was assessed according to RECIST v1.1 or investigator's criteria. We evaluated progression-free survival (PFS) and overall survival (OS) based on dGA.

## Results

Out of 323 pts included, 43 had one dGA: *KRAS*m (26; n=8 G12C), *EGFR*m (8; n=6 del19/ex21), *BRAF*m (5; n=4 V600E) and *ALK*r (4). Median age was 66 [39-84], gender ratio 1:1, with 98% PS ≤1 and 19% non-smokers; 88% had adenocarcinoma. PD-L1 was positive in 85% (n=4 missing). Median PFS was 17.5 months (mo.) (95%CI, 13.2-24.9) and mOS 47 mo. (95%CI, 47-not reached [NR]). No statistically significant differences in terms of mPFS were observed between dGA *vs.* non-dGA pts: 14.9 mo. (95%CI, 8.1-NR) *vs.* 18 mo. (95%CI, 13.4-28.3) (*P*=1.0); mOS was immature. Median PFS and OS rate at 18 mo. by each dGA are detailed in the table.Table: 1172MO

| | PFS mo. (95%CI) | OS rate at 18 mo. % (95%CI) |
|---|---|---|
| Overall dGA | 14.9 (8.1-NR) | 93.4 (84.7-100) |
| *KRAS*m *KRAS*m G12C | NR (14.9-NR)NR (11.3-NR) | 89.7 (76.8-100)87.5 (67.3-100) |
| *EGFR*m *EGFR*mdel19/ex21 | 9 (5.8-NR)8.1 (5.8-NR) | 100 (NR-NR)100 (NR-NR) |
| *BRAF*m *BRAF*mV600E | 3.9 (3.9-NR)8.4 (3.9-NR) | 100 (NR-NR)100 (NR-NR) |
| *ALK*r | 7.8 (7.7-NR) | 100 (NR-NR) |

Within dGA pts, neither OS nor PFS were correlated with PD-L1 expression, whereas PFS was positively associated with smoking status: 19.2 mo. (95%CI, 11.3-NR) *vs.* 5.8 mo. (95%CI, 3.9-NR) in non-smokers (*P*=0.001).

## Conclusions

We observed limited activity of durvalumab consolidation in pts with stage III non-resecable NSCLC with dGA, except for those harbouring *KRAS*m. Larger studies are needed to confirm these findings.

## Legal entity responsible for the study

The authors.


## Funding

Has not received any funding.


## Disclosure

E. Auclin: Financial Interests, Institutional, Other: Mundipharma; Financial Interests, Personal and Institutional, Other: Sanofi Genzymes. R. Lopez Castro: Financial Interests, Institutional, Sponsor/Funding, Advisory role, lectures, other: Roche; Financial Interests, Institutional, Sponsor/Funding: Boehringer Ingelheim; Financial Interests, Institutional, Advisory Role, Lectures, Honoraria, Clinical Research: Bristol Myers Squibb; Financial Interests, Institutional, Advisory Role, Lectures, Honoraria, Clinical Research: AstraZeneca; Financial Interests, Institutional, Advisory Role, Other: Novartis. J. Bosch Barrera: Financial Interests, Personal and Institutional, Research Grant: Roche; Financial Interests, Personal and Institutional, Research Grant: Pfizer; Financial Interests, Personal and Institutional, Other: MSD; Financial Interests, Personal and Institutional, Other: BMS; Financial Interests, Personal and Institutional, Other: AstraZeneca; Financial Interests, Personal and Institutional, Other: Novartis; Financial Interests, Personal and Institutional, Other: Pierre Fabre; Financial Interests, Personal and Institutional, Other: Boehringer Ingelheim. S. Pilotto: Financial Interests, Institutional, Funding, Lectures: Roche; Financial Interests, Institutional, Funding, Lectures: Pfizer; Financial Interests, Institutional, Funding, Lectures: Merck Serono; Financial Interests, Institutional, Funding, Lectures: BMS; Financial Interests, Institutional, Invited Speaker: MSD; Financial Interests, Institutional, Invited Speaker: Lilly; Financial Interests, Institutional, Invited Speaker: Amgen; Financial Interests, Institutional, Invited Speaker: Boehringer Ingelheim; Financial Interests, Institutional, Invited Speaker: AstraZeneca; Financial Interests, Institutional, Invited Speaker: Takeda. M. Tagliamento: Financial Interests, Institutional, Other: Roche; Financial Interests, Institutional, Other: Bristol Myers Squibb; Financial Interests, Institutional, Other: AstraZeneca; Financial Interests, Other: Takeda; Financial Interests, Writing Engagements: Novartis; Financial Interests, Writing Engagements: Amgen. E. Nadal: Financial Interests, Funding, Lectures: Roche; Financial Interests, Funding: Pfizer; Financial Interests, Funding, Lectures: Merck Serono; Financial Interests, Funding, Lectures: BMS; Financial Interests, Advisory Board: MSD; Financial Interests, Advisory Board: Lilly; Financial Interests, Advisory Board: Amgen; Financial Interests, Advisory Board: Boehringer Ingelheim; Financial Interests, Advisory Board: AstraZeneca; Financial Interests, Advisory Board: Takeda. D. Signorelli: Financial Interests, Institutional, Advisory Role: AstraZeneca; Financial Interests, Institutional, Advisory Role: Boehringer Ingelheim; Financial Interests, Institutional, Advisory Role, Other: Merck Sharp & Dohme; Financial Interests, Institutional, Other: Roche; Financial Interests, Institutional, Other: Bristol Myers Squibb. B. Besse: Financial Interests, Institutional, Sponsor/Funding: AbbVie; Financial Interests, Institutional, Sponsor/Funding: Amgen; Financial Interests, Institutional, Sponsor/Funding: AstraZeneca; Financial Interests, Institutional, Sponsor/Funding: BioGene; Financial Interests, Institutional, Sponsor/Funding: Blueprint Medicines; Financial Interests, Institutional, Sponsor/Funding: BMS; Financial Interests, Institutional, Sponsor/Funding: Boehringer Ingelheim; Financial Interests, Institutional, Sponsor/Funding: Celgene; Financial Interests, Institutional, Sponsor/Funding: Cristal Therapeutics; Financial Interests, Institutional, Sponsor/Funding: Daiichi Sankyo; Financial Interests, Institutional, Sponsor/Funding: Eli Lilly; Financial Interests, Institutional, Sponsor/Funding: GSK; Financial Interests, Institutional, Sponsor/Funding: Ignyta; Financial Interests, Institutional, Sponsor/Funding: Ipsen; Financial Interests, Institutional, Sponsor/Funding: Inivata; Financial Interests, Institutional, Sponsor/Funding: Janssen; Financial Interests, Institutional, Sponsor/Funding: Merck KGaA; Financial Interests, Institutional, Sponsor/Funding: MSD; Financial Interests, Institutional, Sponsor/Funding: Nektar; Financial Interests, Institutional, Sponsor/Funding: Onxeo; Financial Interests, Institutional, Sponsor/Funding: OSE Immunotherapeutics; Financial Interests, Institutional, Sponsor/Funding: Pfizer; Financial Interests, Institutional, Sponsor/Funding: PharmaMar; Financial Interests, Institutional, Sponsor/Funding: Roche-Genentech; Financial Interests, Institutional, Sponsor/Funding: Sanofi; Financial Interests, Institutional, Sponsor/Funding: Servier; Financial Interests, Institutional, Sponsor/Funding: Spectrum Pharmaceuticals; Financial Interests, Institutional, Sponsor/Funding: Takeda; Financial Interests, Institutional, Sponsor/Funding: Tiziana Pharma; Financial Interests, Institutional, Sponsor/Funding: Tolero Pharmaceuticals. D. Planchard: Financial Interests, Institutional, Advisory Role, Lectures, Clinical Research, Honoraria, other: AstraZeneca; Financial Interests, Institutional, Advisory Role, Lectures, Honoraria, Clinical Research: Bristol Myers Squibb; Financial Interests, Institutional, Advisory Role, Lectures, Honoraria, Clinical Research: Boehringer Ingelheim; Financial Interests, Institutional, Advisory Role, Lectures, Honoraria, Clinical Research: Celgene; Financial Interests, Institutional, Advisory Role, Lectures, Honoraria, Clinical Research: Daiichi Sankyo; Financial Interests, Institutional, Advisory Role, Lectures, Honoraria, Clinical Research: Eli Lilly; Financial Interests, Institutional, Advisory Role, Lectures, Honoraria, Clinical Research, Other: Merck; Financial Interests, Institutional, Advisory Role, Lectures, Honoraria, Clinical Research, Other: Novartis; Financial Interests, Institutional, Advisory Role, Lectures, Honoraria, Clinical Research, Other: Pfizer; Financial Interests, Institutional, Advisory Role, Lectures, Honoraria, Other: prIME Oncology; Financial Interests, Institutional, Advisory Role, Lectures, Honoraria: Peer CME; Financial Interests, Institutional, Advisory Role, Lectures, Honoraria, Clinical Research, Other: Roche; Financial Interests, Institutional, Principal Investigator: MedImmune; Financial Interests, Institutional, Principal Investigator: Sanofi-Aventis; Financial Interests, Institutional, Principal Investigator: Taiho Pharma; Financial Interests, Institutional, Principal Investigator: Novocure. L. Mezquita: Financial Interests, Institutional, Advisory Role: Roche; Financial Interests, Institutional, Invited Speaker: Bristol Myers Squibb; Financial Interests, Institutional, Invited Speaker: Tecnofarma; Financial Interests, Institutional, Invited Speaker: AstraZeneca; Financial Interests, Institutional, Invited Speaker: Chugai. All other authors have declared no conflicts of interest.